Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Advanced Cancers × Sorafenib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 33 Liver Neoplasms 18 Neoplasms 13 Neoplasm Metastasis 11 Leukemia, Myeloid, Acute 11 Carcinoma, Renal Cell 8 Pancreatic Neoplasms 7 Melanoma 7 Carcinoma, Non-Small-Cell Lung 7 Breast Neoplasms 6 Brain Neoplasms 6 Unspecified Adult Solid Tumor, Protocol Specific 5 Precursor Cell Lymphoblastic Leukemia-Lymphoma 5 Multiple Myeloma 5 Recurrence 4 Prostatic Neoplasms 4 Lung Neoplasms 4 Kidney Neoplasms 4 Glioblastoma 4 Sarcoma 3 Rectal Neoplasms 3 Myelodysplastic Syndromes 3 Leukemia, Lymphocytic, Chronic, B-Cell 3 Colorectal Neoplasms 3 Colonic Neoplasms 3 Urinary Bladder Neoplasms 2 Stomach Neoplasms 2 Solid Tumors 2 Neuroblastoma 2 Myelodysplastic-Myeloproliferative Diseases 2

Interventions

pazopanib 3 Erlotinib Hydrochloride 3 Cetuximab 3 Vorinostat 2 Oxaliplatin 2 Bevacizumab 2 Azacitidine 2 satraplatin 1 ixazomib 1 X-Rays 1 Valproic Acid 1 Trastuzumab 1 Sorafenib 1 Platinum 1 Pemetrexed 1 Magnetic Resonance Spectroscopy 1 Leucovorin 1 Lenalidomide 1 Lapatinib 1 LY 2275796 1 Injections, Subcutaneous 1 Fluorouracil 1 Everolimus 1 Curcumin 1 Crizotinib 1 Capecitabine 1 Albumin-Bound Paclitaxel 1 AH 111585 1 10-propargyl-10-deazaaminopterin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01608139 2012-10-19

Study of Curcumin, Vorinostat, and Sorafenib

M.D. Anderson Cancer Center

Phase 1 Withdrawn

Advanced Cancers

Data powered by HemOnc (CC BY 4.0) Colophon ⚡